Loading...
Loading...
GRAY| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 22.3M |
| Operating I/L | -22.3M |
| Other Income/Expense | 3.1M |
| Interest Income | 0.0M |
| Pretax | -19.3M |
| Income Tax Expense | -6.2M |
| Net Income/Loss | -13.1M |
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company specializing in developing treatments for diseases of the retina and optic nerve. Their lead product candidate, GB-102, is an intravitreal injection designed for the treatment of wet age-related macular degeneration and diabetic macular edema. Additionally, the company is developing GB-102 for diabetic retinopathy and GB-401, an intravitreally injected implant formulation, to address primary open-angle glaucoma.
